Acesso livre
Acesso livre

Revisão breve | Fluvoxamina para pacientes ambulatoriais sintomáticos com COVID-19.

20 Jan, 2022 | 23:12h

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Conteúdos relacionados:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.